

UCLA ALZHEIMER'S CENTER

UCLA ALZHEIMER'S DISEASE CENTER

ALZHEIMER'S DISEASE RESEARCH CENTER OF CALIFORNIA

KATHERINE & BENJAMIN KAGAN ALZHEIMER'S DISEASE TREATMENT PROGRAM

Volume 5, Number 1

Summer 2004

The UCLA Focal-type Dementias Clinic

The UCLA Focal-type Dementias Clinic (FtD) specializes in the diagnosis and management of frontotemporal dementia (FTD) and other focal neurodegenerative dementias such as progressive aphasia, semantic dementia, and posterior cortical atrophy. These disorders affect one specific part of the brain for many years before spreading to other brain regions. Although far less is known about FTD, formerly known as Pick's disease, than about Alzheimer's disease, research during the last ten years has greatly increased our understanding of focal dementias. Discoveries indicate that FTD is not one condition but many related conditions, some with progressive speech and language difficulty or aphasia and others with parkinsonism or other movement disorders. Most FTD patients, however, begin with early and sometimes devastating changes in personality.

The FtD Clinic, which is part of the UCLA Alzheimer's Disease Center (ADC), is directed by Mario F. Mendez, MD, PhD, a behavioral and cognitive neurologist and UCLA Professor of Neurology and Psychiatry and Jill Shapira, RN, PhD, a specialist in dementia care with over twenty years of experience in the management of FTD patients and their caregivers. The FtD clinic evaluates all focal brain degenerations associated with dementia and focuses on the unique problems posed by these disorders. In contrast to AD, focal dementias develop in persons in their forties, fifties, or early sixties, when they are still working or active. Caregivers need particular guidance, information, and strategies focused on the unique behaviors caused by these disorders. For example, in FTD, changes in personality and social behavior can be difficult to understand and manage. Patients with primary progressive aphasia, posterior cortical atrophy, and other focal dementia syndromes also have unique cognitive problems requiring specialized assessment and interventions.

Patients with cognitive or behavioral disorders with a strong suspicion of underlying focal brain degeneration may be referred to the UCLA FtD Clinic for consultation. The evaluation process is usually completed in two visits with scheduled tests between the two appointments and may include a neuropsychological assessment, functional brain imaging, and specialized behavioral testing. In addition, neurogenetic assessment is available. The FtD clinic sends referring clinicians a summary consultation report upon completion of the evaluation. This consultation can provide the patient's physician with medication and behavioral management strategies, or the patient can be managed through the UCLA FtD Clinic. Education and counseling is also provided to patients, families, and caregivers.

To schedule an appointment, please call Jill Shapira, RN, PhD, at (310) 206-6516. Additional information may be obtained from Dr. Mendez (310) 478-3711, ext. 42696 (VA Greater LA Neurobehavior office) or by calling the UCLA Alzheimer's Disease Center at (310) 206-5238.



Jill Shapira, RN, PhD and Mario Mendez, MD

From the Director



ADC Director
Jeffrey L. Cummings,
MD

I am pleased and proud to announce that the UCLA ADC was awarded a five-year renewal of the prestigious Alzheimer's Disease Research Center (ADRC) grant from the National Institute of Health. The renewal represents an endorsement of the research efforts made by our center in the past as well as faith in our plans for the future.

As you will read in the following pages, important new research projects have been funded, exciting clinical trials are on-going, and efforts are continuing to bring the results of research to the health professional, academic, and general public.

Welcome to New Staff Members



Usha Toland, MS, CGC is the new research coordinator for the Alzheimer's Disease Genetics study, a national research project that is trying to determine the genetic risk factors associated with late-onset Alzheimer's disease (see page 4).

She is a board certified genetic counselor who obtained her master's degree from UC Berkeley. She has a strong interest in the genetics of neurodegenerative conditions as well as the psychosocial impact that these diseases have on families.



Julie Jacobson, BA is a new staff member of the Kagan Alzheimer's Disease Treatment Program. She screens and triages all prospective patients for the UCLA Memory Disorders Clinic as well as providing research support to the staff.

Ms. Jacobson graduated from California State University, Los Angeles in 2002 with a BA in Communication Disorders/Speech Pathology. She has decided to change career paths and is preparing to attend nursing school.

ADC News

The UCLA ADC is committed to cultivating cultural competence in its staff and respecting diversity in its patients. The UCLA ADC in collaboration with the USC ADRC and the Alzheimer's Association of Los Angeles, Riverside, and San Bernardino Counties sponsored *Ethnicity and Dementia: Improving Patient Care* on May 26, 2004 at the Radisson Hotel in Culver City. This conference was attended by more than 60 faculty and community health care professionals who came together to learn assessment and diagnostic skills related to dementia in an ethnically diverse patient population. The faculty included: Helena Chui, MD, Director University of Southern California's Alzheimer's Disease Center, Jeanette Hilgert, MSG, MSW, Program Administrator, Health Empowerment Initiative, Venice Family Clinic, and Evelyn Lee Teng, PhD, Professor of Neurology, University of Southern California.

The UCLA ADC presented a colloquium on *Cross-Cultural Issues and Alzheimer's Disease: An African-American Perspective* on May 18, 2004 to UCLA social work students. This training focused on the specific social work issues related to working with African-American families that have a member diagnosed with Alzheimer's disease (AD) or other related dementias. Presenters included: Ernestina Saxton, MD, director, and Gloria Rodriguez, RN, coordinator, Memory Disorder and Cerebral Function Clinic, Drew University, Kathleen Taylor, program manager, Education and Outreach, Alzheimer's Association of Los Angeles, Riverside, and San Bernardino Counties, and Karen Lee, MSW, LCSW, field education consultant, UCLA Department of Social Welfare.



Jeanette Hilgert, MSG, MSW, Venice Family Clinic, and Evelyn Lee Teng, PhD, Professor of Neurology, University of Southern California

Clinic News

The Memory and Disorders Clinic at UCLA is focusing on the struggle to better understand and treat mild cognitive impairments such as MCI (mild cognitive impairment) and CIND (cognitive impairment non-dementia). MCI is a term used to describe individuals with impairment in cognitive function, mainly memory, who function normally in other cognitive areas and who can carry out day-to-day activities without assistance. Individuals with MCI are at increased risk (approximately ten-fold) for developing dementia in subsequent years. CIND, on the other hand, is a condition that causes impairment in one or more non-memory domains (such as language or the ability to plan complex activities), yet still does not meet criteria for dementia. The fate of individuals with CIND is not as clearly defined as those with MCI; therefore, more careful characterization and longitudinal follow-up is required.

The clinic plans to recruit many otherwise healthy MCI and CIND patients as well as normal control individuals that would like to participate in clinical trials and/or be followed longitudinally. We are confident that the support of our community and professional partners together with our own unwavering dedication will help us learn more about the treatment of MCI and CIND. For more information, please contact the UCLA Memory and Disorders Clinic at (310) 825-8908.

The Neuropsychiatric Research Memory Clinic at the Olive View-UCLA Medical Center (OVMC) is embarking on several new ventures. OVMC has established a collaborative working relationship with the Geriatric Department at the Autonomous National University in Mexico (Universidad Nacional Autonoma de Mexico, UNAM). It has helped establish the Treatment Memory Clinic at Olive View-UCLA Medical Center. The Clinic opened its doors May 20, 2004 and is directed by Shelley Wolf, MD. This Clinic provides an important service to patients who are diagnosed at the Memory Clinic and then need to seek treatment. The Memory Clinic continues to address the public through presentations on channels 52/22 Telemundo

and 54 Azteca (KAZA TV). In collaboration with the Department of Aging, One Generation and the Alzheimer's Association, the Memory Clinic celebrated "A Special Day For Caregivers," June 16, 2004 from 9:00 AM until 3:00 PM. The event featured presentations in Spanish on issues related to dementia and health risks factors, as well as other health related information. The event took place at ONE Generation, 18255 Victory Blvd. Reseda, CA 91335. If you are interested in more information or wish to make an appointment for yourself or a loved one, please contact Mary Anne Sanchez at the OV Memory Clinic at (818) 895-9541.

The Memory Disorders and Cerebral Dysfunction Clinic at Charles R. Drew University continues to provide initial and follow-up assessments, as well as special activities for the community in south central Los Angeles. For example, the popular monthly caregiver breakfast has expanded to include a Men's Only support group, facilitated by Dr. Tony Strickland. In addition, several of our caregivers have become involved with the Advocacy Committee of the Alzheimer's Association. Turusew Wilson is a Drew caregiver who arrived at our clinic two years ago desperate for answers and guidance. She found the information she needed, but then she became concerned for those in her community who knew very little about dementia. She took action by hosting a well-attended viewing of "The Forgetting" at a local Ethiopian restaurant. Ms. Wilson went on to receive a full scholarship from the Alzheimer's Association to attend the 16th Annual Public Policy Forum in Washington, D.C. March 20-23, 2004. She now serves not only as a source of information for her friends and family from Ethiopia, but as an advocate in the halls of Congress. Ms. Wilson believes, "The more effectively we communicate with our elected officials, the more effective the representative system of government becomes. There is now real hope for a future without Alzheimer's disease: keep the faith and keep advocating." We at Drew are very proud of caregivers like Turusew who are dedicated to making a difference.

Alzheimer's Disease Genetics Study Seeks Brothers and Sisters with Late-Onset AD

Recent estimates indicate that the number of people with AD will skyrocket in the next few decades to as many as 13 million by 2050. Scientists are eager to speed up research efforts to understand the causes and risk factors for AD. The National Institute on Aging (NIA), a branch of the National Institute on Health (NIH), has established a national program to identify families with multiple members affected with the condition in order to illuminate the underlying disease process of AD, open up novel areas of research, and identify new targets for drug therapy. The UCLA ADC has been selected as one of the study sites to help identify 1,000 families with at least two siblings who have been diagnosed with *late-onset AD* (diagnosed at 60 years or older).

AD genes as well as the genes for other human diseases have been located by studying families with multiple cases of the disease in question. It is very difficult to locate one risk factor gene out of the 30,000 or so genes that are contained within the human cell. Researchers believe that there are other risk factor genes for AD and, to date, have identified 4 different chromosomal regions where these genes could be located. The further collection and analysis of families with multiple affected individuals will help identify these risk factor genes more clearly.

To be eligible to participate in the study, families must have at least 3 living members who can donate a blood sample, including:

- **2 siblings (brothers or sisters) who developed AD after age 60,**
and
- **Another family member over age 50 who may have memory loss OR a family member over age 60 who does not have any memory loss.**

If a family member is no longer living, but there is frozen autopsy tissue available, then the family may still be eligible to participate.

Participants will be asked to complete a telephone or in-person interview to gather medical and family history information, give permission for their medical records to be reviewed, and have a medical exam with memory testing, if needed. Participants also will be

asked to donate a blood sample that will be made into a cell line (a family of cells grown in the laboratory) that will enable the person's DNA to be available to qualified scientists over many years. The data and cell lines will be stored at a central repository at Indiana University's the National Cell Repository for Alzheimer's Disease (NCRAD). An important aspect of the study is patient confidentiality. All blood samples and health information are coded, and identifiers such as name and date of birth are removed from all materials.

Participants may live anywhere in the U.S., and family members do not need to live near each other. There is no cost to participants. Families who are interested in learning more about the Alzheimer's Disease Genetics Study or who would like to participate should contact:

Usha Toland, MS, CGC
Genetic Counselor & Research Coordinator
UCLA Alzheimer's Disease Center
(310) 206-3275
e-mail: utoland@mednet.ucla.edu

Help fund research for the care and cure of Alzheimer's Disease

Enclosed is my tax deductible contribution of _____

Please note that this contribution is in *Memory Of* _ *Honor Of* _

Please send an acknowledgement of this gift to:

Name _____

Address _____

City _____ State _____ Zip _____

Donor Name _____

Address _____

City _____ State _____ Zip _____

Please make checks payable to:

THE UC REGENTS
UCLA Alzheimer's Disease Center
710 Westwood Plaza, Suite 2238
Los Angeles, CA 90095-1769

The Memory Club: An Early Stage Alzheimer's Disease Program

Imagine that you have just been told, “*You have early stage Alzheimer's disease.*” What is early stage AD? You may have noticed some memory lapses, such as forgetting people's names, getting disoriented when driving, or having difficulty with finances. Since many of these changes can be explained by stress or fatigue, why look for a disease diagnosis? However some of these mild symptoms also may be the first signs of early stage AD. Experts have begun to look at AD as a continuum starting with MCI that may or may not lead to early stage AD that then progresses to AD.

A first sign of early stage AD is difficulty remembering recent events. It may be accompanied by signs and symptoms of depression that can exacerbate the memory loss. Recognizing that early stage AD has unique characteristics and special impact on the individual and

family, the Alzheimer's Association of Los Angeles, Riverside and San Bernardino Counties has started an educational support group for people with early stage AD and their families. The program is called the Memory Club. The Memory Club includes an initial family consultation, participation in a ten-week education/support group (information is provided in a large group setting, and there are separate support groups for individuals experiencing memory loss and for their care partners), follow-up family consultations, and finally, for those members interested in the continuation of a group, The Graduation Club. For more information about The Memory Club, please contact Michelle Barclay, MA in the San Fernando Valley at (818) 677-4404 or Michelle De Los Santos, LCSW in the Los Angeles area at (323) 930-6217.

UCLA ADC RESEARCH NEWS

The renewal of the ADRC included funding for three innovative projects:

- George Jackson, MD, PhD, assistant professor in residence, neurology will lead a project to identify and investigate the compounds that suppress neurofibrillary pathology, using the drosophila (fly) model. This project contributes to the commitment of the ADRC to foster research that will lead to identification of disease-modifying therapies for AD and related conditions.
- George Bartzokis, MD, director, UCLA ADC Clinical Core, Arthur Toga, PhD, professor, neurology, and Paul Thompson, PhD, assistant adjunct professor, neurology will lead a project to investigate and apply strategies with unprecedented sensitivity to detect, map, and analyze patterns of brain change (structural and functional) in AD and in those at risk for AD. This project blends neuroscience and engineering strategies to address extremely pressing challenges in medicine.
- Greg Cole, PhD, associate director of the UCLA ADC, and Karen Gylys, PhD, assistant professor, School of Nursing, will lead a project to research the role of oxidative damage in AD pathogenesis and

synapse loss. This project will not only better define the role of oxidative damage, but will also compare current and novel therapeutic agents of direct clinical relevance.

The Alzheimer's Disease Program of the California Department of Health Services awards grants for research projects. The funds for these awards come from California taxpayers who make a tax-deductible contribution on their tax returns. Two ADC investigators have received these grants, starting July 2004. Bruce Teter, PhD, assistant adjunct professor, medicine, will investigate the mechanisms of apolipoprotein E (apoE), the strongest genetic risk factor for sporadic AD. John Ringman, MD, director of the Kagan Treatment Program, will investigate: subtests in validated Spanish neuropsychological batteries to determine if they are sensitive to early AD in pre-clinical carriers of Presenilin-1 (PS1), what psychopathology is prevalent in otherwise pre-symptomatic PS1 mutation carriers, and what biochemical markers of AD are present in persons at-risk for the inheritance of PS1 mutations. These results will assist in the early diagnosis of AD in general and especially in the underserved Hispanic population.

You Can Help Discover the Treatment for Alzheimer's Disease

Researchers have made great strides in the laboratory, contributing immensely to our understanding of the causes and the process of AD. This laboratory work has led to the development of drugs that may be safe and effective for preventing, slowing the course of, and improving the symptoms of AD. A large number of drugs, under the auspices of the National Institute on Aging and private pharmaceutical companies, are in various stages of development. The usefulness of these drugs must be tested on humans in clinical trials. We cannot evaluate potential treatments for preventing or treating AD without the participation of our

generous volunteers.

The UCLA Benjamin and Katherine Kagan Alzheimer's Disease Treatment Program has multiple studies for various stages of the illness. The following chart provides an overview of these studies. If someone you know has been diagnosed with AD or mild cognitive impairment and might be interested in participating, please contact us. We would be very happy to discuss the various clinical trial opportunities and answer your questions or concerns. Please call (310) 206-3779.

Condition Being Studied	Medication Being Tested	Design	Eligibility Criteria
Psychosis and/or agitation in men and women with probable Alzheimer's disease, Parkinson's disease or Dementia with Lewy Bodies	Quetiapine (Seroquel)	<ul style="list-style-type: none"> • Twelve week study • Placebo-controlled • Nine clinic visits with two neurologists • Neuropsychological testing • Clinical Laboratory testing^β • Caregiver needed 	<ul style="list-style-type: none"> ✓ Diagnosis of probable Alzheimer's, Parkinson's disease with Dementia or Dementia with Lewy Bodies ✓ Male or Female 50+ years ✓ Not on psychosis medication ✓ On either Aricept, Reminyl, Exelon and/or Memantine
Dementia and depression in men and women with Alzheimer's disease	No drug treatment	<ul style="list-style-type: none"> • Two clinic visits with neurologist, 3 months apart and 6 phone calls • Questionnaires • Caregiver needed 	<ul style="list-style-type: none"> ✓ Diagnosis of probable Alzheimer's disease ✓ Depressed and non-depressed subjects ✓ Male or Female 50+ years
Mild to moderate Alzheimer's disease in men and women	Simvastatin (Zocor)	<ul style="list-style-type: none"> • 24 week study • Placebo-controlled • Neuropsychological testing • Clinical Laboratory Testing • Eight clinic visits with neurologists • Caregiver needed 	<ul style="list-style-type: none"> ✓ Diagnosis of probable Alzheimer's disease ✓ Male or Female 50+ years ✓ No lipid lowering agents
Mild to moderate Alzheimer's disease in men and women	B Vitamins and Folic Acid	<ul style="list-style-type: none"> • 18 month study • Placebo-controlled • Neuropsychological testing • Clinical Laboratory Testing • Eight clinic visits with neurologists • Caregiver needed 	<ul style="list-style-type: none"> ✓ Diagnosis of probable Alzheimer's disease ✓ Male or Female 50+ years ✓ No lipid lowering agents ✓ No B12 or Folate deficiency
Mild to moderate Alzheimer's disease in men and women	Curcumin	<ul style="list-style-type: none"> • 12 month study • 6 months placebo-controlled, 6 months open label • Neuropsychological testing • Clinical Laboratory Testing • Seven clinic visits with neurologists • Caregiver needed 	<ul style="list-style-type: none"> ✓ Diagnosis of probable Alzheimer's disease ✓ Male or Female 50+ years
Mild to moderate Alzheimer's disease in men and women	Valproate (Depakote)	<ul style="list-style-type: none"> • 26 month study • Placebo-controlled • Neuropsychological testing • Clinical Laboratory Testing • Twelve clinic visits with neurologists • MRI Testing • Caregiver needed 	<ul style="list-style-type: none"> ✓ Diagnosis of probable Alzheimer's disease ✓ Male or Female 50+ years

Thank You

The UCLA Alzheimer's Disease Center would like to thank our many friends and donors for their support in fighting Alzheimer's disease. These private donations help fund the innovative health services and clinical and basic science research projects that support the Center's commitment to improving lives of patients with Alzheimer's disease. If you would like to join this list of friends, please contact Karen Metz, ADC Administrator at (310) 206-5238

Memorial Contributions

VIRGINIA LOUISE ADAMS

by:

Joan & Rebecca A. Caley
Mrs. P. Hoffman
Mr. & Mrs. Konersman
Ms. S. Sato
Thelma Lafer & Associates

RAFFAELLA ELSIE ARMENI

by:

Mr. A. Armeni
Mr. I. Rosenberg

JOHN CLARK BECK, I

by:

Mr. & Mrs. Sargent

BOB BORDER

by:

Ms. M. C. Shaw

LUCILLE M. BUNYARD

by:

Mr. L. Bunyard

MIRIAM BUTCHART

by:

Ms. B. McLaurin

HELEN FEINBERG

by:

Ms. M. Marvick

HARRY J. L. FRANK, JR

by:

Mrs. H. Frank
Mr. J. Frank

KYRLE HATH

by:

Carmen and James Davis
Shirley Snyder & Myrtle Smith
Kinko's, Inc

ESTHER KOZDREY

by:

UCLA Capital Programs Inspection
Department

RUSSELL LAMB

by:

Mr. R. Bartholomew
Ms. F. Dodds

RITA MENDELSON

by:

Mr. S. Laff

VICKI PLOWMAN

by:

Mr. C. T. Grim
Mrs. L. S. Weselman

FRED REITZ

by:

Mr. E. Noneman

PHYLLIS RICHARDSON

by:

Ms. L. Snyder

RACHEL ROONEY

by:

Bill & Miriam Johnson

ALEXANDER SCHREIBER

by:

Norman & Vera Turner

MAXINE SPENCER

by:

Mrs. D. Amigh
Mr. & Mrs. J. Amigh, Sr
Ms. M. Fowler
John & Myra Glowacki
St. Lukes Episcopal Church

MILA THOMAS

by:

The Capital Group Companies Charitable
Foundation

MARGE VILLENEUVE

by:

Mr. R. L. Lacy

Other Contributions:

Aaroe Associates Charitable Foundation
Judge and Mrs. Berenson
Bowen H. & Janice Arthur McCoy Charitable
Foundation
Breslauer and Rutman, LLC
California Community Foundation
Mrs. H. Frank
Mr. J. H. Frank
Mr. J. Gilbert
IBM
Mr. D. C. Kress
Ms. C. Jasinski
Mr. M. Linnit
Long Beach Emblem Club #106
Ann Meyer and Family
The Prudential Foundation
Tichi Wilkerson Kassel Parkinson's
Foundation, Inc.

The UCLA Alzheimer's Disease Center
is funded by the National Institute on
Aging (NIA) and the State of
California for research and
treatment of Alzheimer's disease
and related disorders.

ADMINISTRATION

Jeffrey L. Cummings, MD
Gregory M. Cole, PhD
Karen Metz, MA

CLINICAL CORE

George Bartzokis, MD
Po Lu, PsyD
Michele Carter, RN
Usha Toland, MS, CGC

KAGAN TREATMENT PROGRAM

John Ringman, MD
Kavita Shankar, PhD

OLIVE VIEW MEDICAL CENTER

L. Jaime Fitten, MD
Freddy Ortiz, MA
Mary Anne Sanchez

CHARLES R. DREW UNIVERSITY

Tony Strickland, PhD
Ernestine Saxton, MD
Paul Longobardi, PhD
David Richardson, PhD
Gloria Rodriguez, RN

NEUROPATHOLOGY AND MOLECULAR GENETICS

Harry Vinters, MD
Dan Geschwind, MD, PhD
Dennis Chute, MD
Martina Wiedau-Pazos, MD, PhD

EDUCATION AND INFORMATION TRANSFER

Janet Frank, DrPH
Diane Katz, MA, MPH

DATA MANAGEMENT

Jim Mintz, PhD
Sun Hwang, MPH

IMAGING

Gary Small, MD
Arthur Toga, PhD
Dan Silverman, MD, PhD
George Bartzokis, MD

BASIC SCIENCE

Greg Cole, PhD
Sally Frautschy, PhD
Paul Thompson, PhD
George Jackson, MD, PhD

TRANSLATION/HEALTH SERVICES

Barbara Vickrey, MD, MPH

UCLA Alzheimer's Disease Center

General Information (310) 206-5238

The **UCLA ADC Newsletter** is published semi-annually by the UCLA Alzheimer's Disease Center. To add or change your mailing address to this publication, or for any inquiries, please contact:

UCLA ADC Newsletter
710 Westwood Plaza, Suite 2238
Los Angeles, CA 90095-1769

Editors

Jeffrey L. Cummings, MD
Janet C. Frank, DrPH
Diane C. Katz, MA, MPH

Photography

Alan Braus
Diane Katz
Karen Metz

Clinical Appointments

Memory Disorders Clinic
UCLA Medical Center
300 UCLA Medical Plaza,
Suite B200
Los Angeles, CA 90095
(310) 794-1195

**Memory Disorder and Cerebral
Dysfunction Clinic**
**Drew University School of
Medicine**
1720 East 120th Street, Room 2194
Los Angeles, CA 90059
(323) 563-5915

**Neuropsychiatry Research
Memory Clinic**
Olive View Medical Center
14445 Olive View Drive
Sylmar, CA 91342-1495
(818) 895-9541

Website:
<http://www.adc.ucla.edu>

2004 ADC and Geriatric Medicine Educational Programs

SEPT. 29 - OCT. 2, 2004
**21st Annual Intensive Course in
Geriatric Medicine and
Board Review**

**Intensive Course in Geriatric
Pharmacy and Board Review**
Marina del Rey, California

For additional information,
please contact Mr. Lucio Arruda at
(310) 312-0531; larruda@ucla.edu

UCLA ALZHEIMER'S DISEASE CENTER

710 WESTWOOD PLAZA, SUITE 2238
LOS ANGELES, CA 90095-1769

Non-Profit Org.
U.S. Postage
PAID
UCLA